TrialClinical genitourinary cancer2018

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Edoardo Francini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.